If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"COPEDOL","allocation":"","arm_groups":[{"arm_group_label":"HIV-1 infected patients","arm_group_description":"Pretreated patient (aged 18 years or more) failing therapy and receiving dolutegravir (TIVICAY or TRIUMEQ) for the 1st time from 01 Feb 2014","arm_type":""}],"assignment":"","brief_summary":"A 2-year follow up study of a national, longitudinal, multicentre, historical-prospective, observational pharmacoepidemiological cohort in the hospital by physicians experienced in the management of HIV in HIV-1-infected patients, pretreated, failing therapy and initiating treatment with dolutegravir. Treatment failure means virologic failure (viral load > 50 cp/ml with or without resistance and whatever the cause, including non-compliance), or \"clinical or biochemical toxicity or intolerance to one or more ART\". Several data collection times are planned: at baseline (initiation of dolutegravir), and at each naturalistic (i.e. not protocolised) follow-up visit of the patient over a period of 2 years. Patients are recruited retrospectively, with retrospective and/or prospective follow-up according to the date of initiation of dolutegravir.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A 2-year follow-up study of a longitudinal, multicentre, historical-prospective, observational pharmacoepidemiological cohort of pretreated HIV-1-infected patients with treatment failure and initiating treatment with dolutegravir, in France","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus I","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:15:47","criteria":"Inclusion Criteria: - HIV-1 infected patient; - Adult patient (aged 18 years or more); - Pretreated patient failing therapy and receiving dolutegravir (TIVICAY or TRIUMEQ) for the 1st time from 01/02/2014; - Patient who received the information sheet and gave his/her verbal agreement to participate in the study. Exclusion Criteria: - Patients already enrolled in a clinical trial.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"500","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"b95613ba-b63c-5a01-bfd1-490bb6e23f09","internal":{"content":null,"contentDigest":"6c148530ee10a88e89b622a6a765c7fd","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - HIV-1 infected patient; - Adult patient (aged 18 years or more); - Pretreated patient failing therapy and receiving dolutegravir (TIVICAY or TRIUMEQ) for the 1st time from 01/02/2014; - Patient who received the information sheet and gave his/her verbal agreement to participate in the study. Exclusion Criteria: - Patients already enrolled in a clinical trial.","interventions":[{"arm_group_label":"HIV-1 infected patients","intervention_description":"Not applicable","intervention_name":"Dolutegravir","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"03/01/2019 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18","minimum_age_raw":"18 Year","modified_date":"10/01/2018 22:39:43","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None retained","number_of_groups":"","observational_study_design":"Cohort","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Other"},"official_title":"A 2-year follow-up study of a longitudinal, multicentre, historical-prospective, observational pharmacoepidemiological cohort of pretreated HIV-1-infected patients with treatment failure and initiating treatment with dolutegravir, in France","org_study_id":"205255","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["France: : National Commission for Computing and Liberties (CNIL)","France: CCTIRS : Advisory Committee on Information Processing in Material Research in the Field of Health (CCTIRS)","France: : National Council of Physicists/Pharmacists (CNOM - CNOP)"]},"phase":"phase 4","primary_compl_date":"03/01/2019 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"o time to virologic suppression (Viral Load (VL) < 50 copies/ml)","outcome_time_frame":"Not applicable","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"o virologic response (viral load < 50 copies/ml)","outcome_time_frame":"at each follow-up time","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"CV","outcome_time_frame":"Not aplicable","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"CD4 count","outcome_time_frame":"at each follow-up time","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"genotypic resistance before initiation of DTG, treatment regimens and patterns of prescription","outcome_time_frame":"Baseline","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"adverse reactions and reasons for discontinuation/treatment adjustment and pregnancy","outcome_time_frame":"throught the study","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"time to escape from dolutegravir treatment in patients with virologic success at baseline","outcome_time_frame":"Not Applicable","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"percentage of patients still receiving dolutegravir at the end of each year of follow-up","outcome_time_frame":"M12 and M24","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"genotypic resistance","outcome_time_frame":"Resistance mutations occurring in patients treated with dolutegravir","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of patients with VL < 50 copies/ml among patients still receiving dolutegravir on M24","outcome_time_frame":"M24","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"hospitalizations, outpatient visits, antiretroviral therapy, CD4 count tests and measurements of viral load, genotypic resistance testing; assays of ART","outcome_time_frame":"Not applicable","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"socio-demographic data, history of HIV infection, comorbidities and co-infections, genotypic profile, previous treatments","outcome_time_frame":"Baseline","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"hospitalizations, opportunistic infections and AIDS-defining events or deaths","outcome_time_frame":"Not applicable","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"treatment regimens","outcome_time_frame":"Baseline","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"09/01/2016 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"205255"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}